Monoclonal Antibody Discovery
Get fully human mAb leads with the binding properties, developability data, and functional validation your program needs on clinically validated frameworks.
Traditional mAb discovery gives you too few candidates while introducing unnecessary developability risk. While conventional campaigns are still in their first round of boosts, our phage display engine has already delivered your lead panel — fully human, developability-assessed, and ready to advance. No immunization. No humanization.
Target specific binding properties from the start. Don't defer to later, more expensive project stages.
We built our libraries on clinically validated human germline frameworks. No humanization engineering needed downstream.
Unlike others, we publish our pricing. Build your business case on your own time without the typical runaround.
Every campaign runs 90+ screens. The modality determines how they’re optimized. You pick.
Affinity + diversity
What it is: Broad panels that optimize affinity and epitope diversity at the same time.
Use it when: The default when you don’t have a strong directional hypothesis. Gives you the widest starting panel.
Max building potency
What it is: Screens tuned to maximize binding potency.
Use it when: High-potency binding matters more than panel diversity.
Max distinct epitopes
What it is: Non-competing candidate panels that maximize the number of distinct epitopes represented.
Use it when: You're building toward a bispecific program and need antibodies that don't compete with each other.
Target specific sites
What it is: Screens directed at specific pharmacological sites — blocking, activating, or engaging defined receptor interfaces.
Use it when: You know exactly where you need to bind.
Multi-species binding
What it is: Human/cyno or human/rodent cross-reactivity built into the selection pressure. Off-target exclusion available.
Use it when: Your program has preclinical species requirements and you want cross-reactivity designed in, not just tested for afterward.
pH or TME-selective
What it is: Antibodies that bind only under specific conditions — acidic pH, tumor microenvironment.
Use it when: you need context-specific engagement — e.g., activity in the tumor but not in healthy tissue.
Most programs add structured characterization beyond what’s included in the matrix screening: biophysical, binding kinetics, and formulation. We run all of it in-house. You don’t need another outsourced partner or potential in-house lab delays.
BIO
Carterra LSA high-throughput binding kinetics and epitope diversity, validated cell binding analysis, in silico liability scanning, mass spec for intact mass confirmation, full developability assay panel, and high-concentration formulation optimization.
DEV
Expression and purity, thermal stability, self-association, aggregation, solubility, immunogenicity risk, viscosity, each measured with a validated technique. The full developability data sits behind every lead candidate we hand off.
Most discovery services run a few libraries and hope for the best. We run 30 in parallel — 90 screens at once — because the only way to find the best binder is to never stop looking for a better one. We spent 14 years building libraries that don't need humanization afterward, on frameworks selected for the properties that actually matter in the clinic. That's not something you can shortcut."
“The team at Invenra is highly professional, timely with milestones, demonstrate clear expertise and scientific rigor, and offer an extraordinarily unique platform that has yielded high-confidence results, despite an exceedingly challenging target.”
“Invenra and its technology are top-notch. I have and will continue to recommend the Invenra team to anyone seeking novel antibody discovery, bispecific and trispecific antibody development, and novel ADC development.”
"Top-tier platform combined with top-tier people. A team that has collaborated to drive our programs forward with speed and scientific rigor, even providing services like specialized in vitro assays and efficacy models."
"The level of customization and partnership support is unparalleled relative to the other groups we evaluated for our company."
“We have worked with over 20 platforms, and the B-Body was the highest-yielding, easiest to work with bispecific platform.”